search button

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer

  • Authors:
    • Lin Yang
    • Yi Yang
    • Qiong Qin
    • Aiping Zhou
    • Jianjun Zhao
    • Jinwan Wang
    • Chang Shu
    • Xinghua Yuan
    • Songnian Hu

  • View Affiliations

  • Published online on: December 22, 2014     https://doi.org/10.3892/ol.2014.2821
  • Pages: 1451-1457
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer (GC) is the second leading cause of cancer‑related mortality worldwide. The usual treatment of GC consists of surgery with additional adjuvant chemotherapy. In the present study, the feasibility and safety of adjuvant S‑1 plus oxaliplatin (SOX) chemotherapy for patients with GC and the optimal dosage of S‑1 were determined. Eligible patients were randomly assigned to either arm A (30 cases) receiving 70 mg/m2 S‑1 (in two seperate half doses) daily or arm B (30 cases) receiving 80 mg/m2 S‑1 (in two seperate half doses) daily. The S-1 was administered twice daily for 14 days followed by a 7‑day rest period for the third week. A total of 130 mg/m2 oxaliplatin was administered on day 1 every 3 weeks for each arm. The cumulative rates of the relative total administration dose of S‑1 at 100% in the 6th treatment course was 71.4% [95% confidence interval (CI), 56.5‑90.3%] in arm A, which was significantly higher than 21.4% (95% CI, 10.5‑43.6%) in arm B (P=0.001). The most common grade 3/4 toxicities were neutropenia (19.6%), thrombocytopenia (19.6%) and vomiting (16.1%). Grade 3/4 thrombocytopenia was observed in 7.1% of patients in arm A and in 32.1% of patients in arm B (P=0.019). With regard to the adverse events induced by S‑1 administration, the incidence of diarrhea (3.6 vs. 42.9%; P<0.001) was significantly higher in arm B than in arm A, as anticipated. Collectively, adjuvant SOX therapy for GC is feasible and safe, and when combined with 130 mg/m2 oxaliplatin, 70 mg/m2/day S‑1 appears to the optimal dose.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 9 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yang L, Yang Y, Qin Q, Zhou A, Zhao J, Wang J, Shu C, Yuan X and Hu S: Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer. Oncol Lett 9: 1451-1457, 2015
APA
Yang, L., Yang, Y., Qin, Q., Zhou, A., Zhao, J., Wang, J. ... Hu, S. (2015). Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer. Oncology Letters, 9, 1451-1457. https://doi.org/10.3892/ol.2014.2821
MLA
Yang, L., Yang, Y., Qin, Q., Zhou, A., Zhao, J., Wang, J., Shu, C., Yuan, X., Hu, S."Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer". Oncology Letters 9.3 (2015): 1451-1457.
Chicago
Yang, L., Yang, Y., Qin, Q., Zhou, A., Zhao, J., Wang, J., Shu, C., Yuan, X., Hu, S."Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer". Oncology Letters 9, no. 3 (2015): 1451-1457. https://doi.org/10.3892/ol.2014.2821